Semaglutide Shows Potential to Slow Biological Aging

A May 19, 2026, study suggests GLP-1 drugs may influence markers of aging in adults with HIV.

Updated on Oct. 19, 2026 in Weight Loss

Semaglutide Shows Potential to Slow Biological Aging

Live Poll

Should pharmaceutical drugs be tested and repurposed to slow down the natural human aging process?

A clinical analysis published on May 19, 2026, reveals that semaglutide slowed biological aging in adults with HIV. Researchers observed these effects through tracking DNA methylation changes over a 32-week period.

Why it matters

Scientists are investigating whether GLP-1 medications can be repurposed to combat aging processes beyond their primary uses. Future trials are essential to determine if these drugs provide similar benefits to healthy populations.

In a trial of 108 adults, the semaglutide group demonstrated a 9% slower aging rate on the DunedinPACE clock during a 32-week period. Additional research on female mice showed a median lifespan of 834 days following treatment.

The players

ARPA-H

This federal agency funds high-impact research to solve difficult health challenges through breakthrough medical technologies.

Novo Nordisk

This global pharmaceutical company specializes in diabetes care, obesity treatment, and other chronic diseases.

Eli Lilly

This major pharmaceutical firm develops medicine for various conditions, including metabolic disorders and autoimmune diseases.

The details

The HIV trial, originally designed to monitor visceral fat changes, utilized DNA methylation data from 84 participants to assess biological clocks. Researchers are now looking toward broader applications, including a study funded by ARPA-H that examines the drug's effects in healthy adults over 60.

January 2026: ARPA-H funded a study on healthy adults.
May 19, 2026: Analysis published in Nature Communications.
June 11, 2026: University of California announced study results.
September 2, 2026: Berkeley mouse study published in Nature.
October 6, 2026: Novo and Lilly presented results at conference.

The Big Picture

This study aligns with the broader mission of the Advanced Research Projects Agency for Health to fund ambitious, high-risk research into human health span. It marks a shift toward investigating whether weight-loss medications could serve as therapeutic agents for aging.

While these findings indicate potential for future anti-aging applications, the medication is currently prescribed for specific metabolic conditions. Patients should consult healthcare providers about established uses and avoid self-medicating for unproven longevity benefits.

The takeaway

Current research provides an early, experimental look at how GLP-1 drugs affect epigenetic markers in specific patient populations. Results from larger, prospective trials are needed before any clinical conclusions about aging can be applied to the general public.